Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market Forecast to 2017
This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017.
The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%.
Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimer’s disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.
It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 30% in the developing markets of the Asia-Pacific region, including India, Australia, and South Korea, between 2010 and 2030. The scheduled shutdown of the NRU reactor in Canada in 2016 and OSIRIS in France in 2018 will not have any major impact in the near future, since demand in this geographic region is compensated by local reactors such as ANSTO. Radiopharmaceuticals are under clinical trials to extend applications. For instance, preference for radiopharmaceuticals in neurological indications such as Alzheimer’s, Parkinson’s, and dementia are increasing besides conventional applications such as cardiology and oncology. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.
Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras, installed in about 1120 institutions; PET diagnosis has increased dramatically after 2002. The total number of PET institutes in Japan has increased around 6-7 times in the last 10
The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%.
Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimer’s disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.
It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 30% in the developing markets of the Asia-Pacific region, including India, Australia, and South Korea, between 2010 and 2030. The scheduled shutdown of the NRU reactor in Canada in 2016 and OSIRIS in France in 2018 will not have any major impact in the near future, since demand in this geographic region is compensated by local reactors such as ANSTO. Radiopharmaceuticals are under clinical trials to extend applications. For instance, preference for radiopharmaceuticals in neurological indications such as Alzheimer’s, Parkinson’s, and dementia are increasing besides conventional applications such as cardiology and oncology. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.
Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras, installed in about 1120 institutions; PET diagnosis has increased dramatically after 2002. The total number of PET institutes in Japan has increased around 6-7 times in the last 10